Calabasas-based KYTHERA Biopharmaceuticals, a developer of aesthetic medicine products aimed at reducing fat deposits, has priced its IPO at $16.00 per share. The firm is offering 4,400,000 shares of its common stock on the NASDAQ Global Select Market as KYTH. The firm priced at the high end of its estimated initial public offering range, which was between $14.00 and $16.00 per share. KYTHERA is venture backed by Versant Ventures, ARCH Ventures, Prospect Venture Partners, JAFCO, Fidelity, among others.